Juvenile myasthenia gravis: From diagnosis to treatment

Diana Castro

Research output: Chapter in Book/Report/Conference proceedingChapter


Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction at the postsynaptic motor end plate, resulting in damage to the structure or function of the acetylcholine receptors. Juvenile myasthenia gravis presents with fluctuating muscle weakness and fatigue before the age of 19 years. These symptoms can affect the oculomotor musculature, bulbar system or have a generalized involvement. The diagnosis is similar to that in adults, made using electrophysiological techniques and antibody testing. Treatment is divided into medical and surgical. The medical management is oriented towards acetylcholinesterase inhibitors, immunosuppression and immunomodulation, including the use of steroids, intravenous immunoglobulin and plasmapheresis. Steroid sparing agents can be used with caution in refractory cases. Surgical approach is based on thymectomy. Future research, ideally prospective randomized controlled data, is needed to understand the differences between the adult and pediatric population, efficacy of therapies and outcomes.

Original languageEnglish (US)
Title of host publicationNovel Challenges in Myasthenia Gravis
PublisherNova Science Publishers, Inc.
Number of pages15
ISBN (Print)9781634830003, 9781634829779
StatePublished - Jul 1 2015

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Juvenile myasthenia gravis: From diagnosis to treatment'. Together they form a unique fingerprint.

Cite this